GENETIC POLYMORPHISMS IN DRUG-METABOLISM

被引：4

作者：

ALVAN, G

机构：

来源：

JOURNAL OF INTERNAL MEDICINE | 1992年 / 231卷 / 06期

关键词：

D O I：

10.1111/j.1365-2796.1992.tb01241.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：571 / 573

页数：3

共 18 条

[1] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].

ALVAN, G ;

BECHTEL, P ;

ISELIUS, L ;

GUNDERTREMY, U .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537

[2] CLINICAL CONSEQUENCES OF POLYMORPHIC DRUG OXIDATION [J].

ALVAN, G .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1991, 5 (03) :209-228

[3] SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].

ANDERSSON, T ;

REGARDH, CG ;

DAHLPUUSTINEN, ML ;

BERTILSSON, L .

THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416

[4] IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].

BERTILSSON, L ;

HENTHORN, TK ;

SANZ, E ;

TYBRING, G ;

SAWE, J ;

VILLEN, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355

[5] PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].

BERTILSSON, L ;

LOU, YQ ;

DU, YL ;

LIU, Y ;

KUANG, TY ;

LIAO, XM ;

WANG, KY ;

REVIRIEGO, J ;

ISELIUS, L ;

SJOQVIST, F .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397

[6] GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN [J].

EVANS, DAP ;

MANLEY, KA ;

MCKUSICK, VA .

BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) :485-491

[7]

EVANS DAP, 1986, ETHNIC DIFFERENCES R, P209

[8]

HAMMER WOLFGANG, 1967, LIFE SCI, V6, P1895, DOI 10.1016/0024-3205(67)90218-4

[9] GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION [J].

HEIM, M ;

MEYER, UA .

LANCET, 1990, 336 (8714) :529-532

[10]

HELSBY NA, 1990, BR J CLIN PHARM, V30, P288

← 1 2 →